Melanoma in adults aged 18 to 39.
Official title: Demographic, Clinical, Dermoscopic, Phenotypic and Genetic Characteristics of Adult Patients With Melanoma Diagnosis <40 Years Age. A Prospective, Monocentric Observational Study
Run by Ente Ospedaliero Ospedali Galliera · NCT06994208 · Data updated 2026-11-12
This project will collect clinical, dermoscopic, pathology, and molecular data to see how common melanoma is and what risk factors and skin features it has in people aged 18–39.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 39 Years |
| Sex | All |
| Enrollment | 25 (estimated) |
| Sponsor | Ente Ospedaliero Ospedali Galliera Academic / other |
| Locations | 1 site (Genoa, Liguria) |
| Status | Recruiting |
| Started | December 2, 2025 |
| Main results expected | September 1, 2027 |
| Study ends | August 31, 2028 |
| Registry record updated | December 19, 2025 |
| Trial ID | NCT06994208 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 to 39 with a diagnosis of cutaneous melanoma (including non-primary lesions) who can provide written informed consent.
✕Probably not a fit
People outside the 18–39 age range, those with non-cutaneous melanoma, or those expecting experimental treatment should not expect direct therapeutic benefit from this observational project.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This observational cohort will gather clinical records, dermoscopic images, and histopathology from patients aged 18–39 diagnosed with cutaneous melanoma at E.O. Ospedali Galliera in Genoa. Investigators will record demographics, known risk factors, lesion phenotype, and dermoscopic features and correlate these with histological findings. Available tumor samples will be tested for BRAF mutations to explore molecular patterns in young patients. The analysis will describe prevalence in this age group and relate clinical appearance to pathology and mutation status.
Why it matters
Potential benefit: If successful, the findings could help clinicians recognize melanoma earlier in young adults and guide prevention and follow-up strategies.
How similar studies have gone: Previous observational series have described risk factors, dermoscopic features, and BRAF mutation frequencies in younger melanoma patients, so this work builds on established findings.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. written informed consent 2. age \> 18 years and \< 40 years 3. diagnosis of cutaneous melanoma even non-primary Exclusion Criteria: \-
Where it's running
-
E.O. Ospedali Galliera
Genoa, Liguria, Italy Recruiting
Study contacts
- Principal investigator: Sanja Javor — Ente Ospedaliero Ospedali Galliera
- Study coordinator: Sanja Javor, MD
- Email: sanja.javor@galliera.it
- Phone: +390105634271
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Personalized adapted exercise program for advanced melanoma
This will try a personalized adapted physical activity program for adults with advanced melanoma who are receiving immunotherapy or targeted therapy.
-
Combining toripalimab and endostatin for treating stage II melanoma
This study is testing if combining a new cancer drug with another treatment can help people with stage II melanoma live longer without their cancer coming back after surgery.
-
Measuring metabolites in melanoma patients using advanced techniques
This study is testing if analyzing blood and other body fluids from melanoma patients can help spot the disease earlier and track any changes in their condition.
-
Investigating melanoma in children, adolescents, and young adults
This study is trying to learn more about melanoma in kids, teens, and young adults to help improve how it's diagnosed and treated.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.